Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCreo Medical Regulatory News (CREO)

Share Price Information for Creo Medical (CREO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.50
Bid: 33.00
Ask: 34.00
Change: -0.50 (-1.47%)
Spread: 1.00 (3.03%)
Open: 33.75
High: 33.75
Low: 33.50
Prev. Close: 34.00
CREO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Disposal

18 Jan 2010 07:00

RNS Number : 6804F
China Real Estate Opportunities PLC
18 January 2010
 



China Real Estate Opportunities plc

Disposal of Tangdao Bay investment at 10.9% premium to independent valuation

China Real Estate Opportunities plc ("CREO" or the "Company"), an AIM listed property company with an established investment and development property portfolio in China, today announces that it has executed an unconditional contract to dispose of its 50% interest in the Tangdao Bay joint venture development. 

CREO's 50% interest in the joint venture has been sold to its partner in the project, SIIC Shanghai Holdings Company ("SIIC"). The sale price was based on a property value of RMB1.389bn representing a 10.9% premium to the most recent independent valuation in June 2009. Net cash proceeds from the transaction amount to £33.8 million at today's exchange rates with no borrowings to be repaid from the sale proceeds and will be received upon the completion of the standard PRC regulatory procedures for the offshore repatriation of proceeds of domestic asset sales.

The sale price reinforces CREO's reported NAV, and follows on from the June 2009 disposal of CREO's interest in the City Centre 5 development at an 8.9% premium to the independent valuation of 31 December 2008.

Furthermore the Company announces that due to the contracted disposal of Tangdao Bay, it has decided not to proceed with the issuance of zero dividend preference shares. In November 2009 the Company announced it was considering such an issuance to facilitate the repurchase of the Company's own ordinary shares which are trading at a significant discount to net asset value. Accordingly the Company proposes to commit up to £15 million from its cash resources to fund a tender offer for its own shares upon receipt of the Tangdao Bay sale proceeds.

At the same time the Company continues to work with its advisers to generate third party demand for its shares.

Commenting, Ray HorneyCREO Chairman said: "The CREO Board is very pleased to announce the execution of an unconditional contract for the disposal of its 50% ownership of the Tangdao Bay development, reinforcing the strength of CREO's balance sheet and underpinning its published net asset value as this sale represents the second asset disposal in the past 6 months above independent valuation. This transaction reinforces the Company's strategy of focussing on its core investment and development assets, particularly in Shanghai, and will further strengthen the Company's cash position and provide a strong platform for the Company to move forward in 2010 and beyond." 

"This sale is timely and as such it is appropriate for the Company to cancel the zero dividend preference share issue and propose the allocation of a prudent sum from its own cash reserves to underwrite its earlier commitment to a repurchase of the Company's own shares."

ENDS

Contact:

CREO

Ray Horney, Chairman

Tel: + 44 (0)1273 775225

Sarah Moriarty, Investor Relations 

Tel: +353 1 6189455

Matrix Corporate CapitalPaul Fincham, Rob Naylor Tel +44 (0)20 3206 7175

Davy

Des Carville

Tel: +353 1 679 6363

Citigate Dewe Rogerson Limited

Tom Baldock

Tel: + 44 (0) 20 7638 9571

Murray Consultants

Ed Micheau

Tel: + 3531 498 0300

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISDBGDBISBBGGR
Date   Source Headline
31st Dec 20217:00 amRNSTotal Voting Rights
23rd Dec 20217:00 amRNSExercise of Options
30th Nov 20217:00 amRNSTotal Voting Rights
24th Nov 20217:00 amRNSExercise of Options
12th Nov 20217:00 amRNSAcquisition of Aber Electronics Limited
11th Nov 20217:00 amRNSAppointment of Joint Broker
30th Sep 202112:00 pmRNSTotal Voting Rights
30th Sep 20217:00 amRNSHalf-year Report
9th Sep 202111:23 amRNSDirector/PDMR Shareholding
8th Sep 20213:59 pmRNSHolding(s) in Company
16th Aug 20213:34 pmRNSOpen Offer Launch, Posting of Circular & GM Notice
13th Aug 20214:45 pmRNSResult of Placing
12th Aug 20215:37 pmRNSProposed Placing & Open Offer, Launch of ABB
30th Jul 20215:00 pmRNSTotal Voting Rights
20th Jul 20213:42 pmRNSShare Awards, Director Dealings & Issue of Equity
16th Jul 20217:00 amRNSOpening of United States East Coast Headquarters
1st Jul 20218:00 amRNSIssue of Equity
30th Jun 202110:30 amRNSResult of AGM
16th Jun 20217:00 amRNSMicroBlate Fine’s first in-human use update
14th Jun 20217:00 amRNSAcquisition of freehold site for £4.25m
4th Jun 20217:01 amRNSNotice of AGM
4th Jun 20217:00 amRNSFinal Results
26th May 20217:00 amRNSFurther health economics data validates technology
19th May 20217:00 amRNSTrading Update
30th Apr 20217:00 amRNSTotal Voting Rights
19th Apr 20217:00 amRNSExercise of Options
19th Feb 202111:31 amRNSHolding(s) in Company
17th Feb 20217:00 amRNSTrading update
7th Jan 20217:00 amRNSUS FDA clearance for MicroBlate™ Flex device
9th Dec 202011:06 amRNSSecond Price Monitoring Extn
9th Dec 202011:00 amRNSPrice Monitoring Extension
9th Dec 20207:00 amRNSFirst clinical use of new Creo GI product
24th Nov 20201:36 pmRNSExercise of Options
3rd Nov 20207:00 amRNSAcquisition of Boucart Medical SRL
2nd Nov 20207:00 amRNSUS FDA clearance for MicroBlate™ Fine device
23rd Sep 20207:00 amRNSHalf-year Report
26th Aug 20204:09 pmRNSHolding(s) in Company
11th Aug 20207:00 amRNSExercise of Options
3rd Aug 20207:00 amRNSVideo abstract published endorsing Speedboat
24th Jul 202011:00 amRNSDirector/PDMR Shareholding
24th Jul 20207:00 amRNSAcquisition of Albyn Medical S.L.
13th Jul 202010:37 amRNSSecretary of State for Wales site visit
13th Jul 202010:08 amRNSSecretary of State for Wales site visit
6th Jul 20207:00 amRNSDirectorate Change
2nd Jul 20207:00 amRNSDevelopment loan for plasma sterilising product
24th Jun 202010:30 amRNSResult of AGM
15th Jun 20207:00 amRNSCE mark for five new devices
8th Jun 20207:00 amRNSIET Prize nomination
3rd Jun 20207:00 amRNSPositive NHS health economics data
27th May 20207:00 amRNSPosting of Annual Report & Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.